1 study found for:    NCT00585195
Show Display Options
Rank Status Study
1 Recruiting A Study Of Oral PF-02341066, A c-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer
Conditions: Non-Small Cell Lung Cancer (ALK-positive);   Non-Small Cell Lung Cancer (c-Met-amplified);   Non-Small Cell Lung Cancer (ROS Marker Positive);   Systemic Anaplastic Large-Cell Lymphoma
Interventions: Drug: PF-02341066;   Drug: Rifampin;   Drug: Itraconazole

Indicates status has not been verified in more than two years